149 related articles for article (PubMed ID: 31583781)
1. Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways.
Muraoka H; Yoshimura C; Kawabata R; Tsuji S; Hashimoto A; Ochiiwa H; Nakagawa F; Fujioka Y; Matsuo K; Ohkubo S
Cancer Sci; 2019 Dec; 110(12):3802-3810. PubMed ID: 31583781
[TBL] [Abstract][Full Text] [Related]
2. TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.
Ochiiwa H; Ailiken G; Yokoyama M; Yamagata K; Nagano H; Yoshimura C; Muraoka H; Ishida K; Haruma T; Nakayama A; Hashimoto N; Murata K; Nishimura M; Kawashima Y; Ohara O; Ohkubo S; Tanaka T
Oncogene; 2021 Feb; 40(7):1217-1230. PubMed ID: 33420360
[TBL] [Abstract][Full Text] [Related]
3. TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.
Yoshimura C; Muraoka H; Ochiiwa H; Tsuji S; Hashimoto A; Kazuno H; Nakagawa F; Komiya Y; Suzuki S; Takenaka T; Kumazaki M; Fujita N; Mizutani T; Ohkubo S
Mol Cancer Ther; 2019 Jul; 18(7):1205-1216. PubMed ID: 31092565
[TBL] [Abstract][Full Text] [Related]
4. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-Martínez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
[TBL] [Abstract][Full Text] [Related]
6. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.
Godbersen JC; Humphries LA; Danilova OV; Kebbekus PE; Brown JR; Eastman A; Danilov AV
Clin Cancer Res; 2014 Mar; 20(6):1576-89. PubMed ID: 24634471
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
McMillin DW; Jacobs HM; Delmore JE; Buon L; Hunter ZR; Monrose V; Yu J; Smith PG; Richardson PG; Anderson KC; Treon SP; Kung AL; Mitsiades CS
Mol Cancer Ther; 2012 Apr; 11(4):942-51. PubMed ID: 22246439
[TBL] [Abstract][Full Text] [Related]
8. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
9. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
10. Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.
Godbersen JC; Paiva C; Danilova OV; Berger A; Brown JR; Danilov AV
Leuk Lymphoma; 2015 May; 56(5):1566-9. PubMed ID: 26086969
[TBL] [Abstract][Full Text] [Related]
11. The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1
El-Mesery M; Rosenthal T; Rauert-Wunderlich H; Schreder M; Stühmer T; Leich E; Schlosser A; Ehrenschwender M; Wajant H; Siegmund D
Cell Death Dis; 2019 Aug; 10(8):611. PubMed ID: 31406107
[TBL] [Abstract][Full Text] [Related]
12. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
13. 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo.
Ito K; Nakazato T; Xian MJ; Yamada T; Hozumi N; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
Cancer Res; 2005 May; 65(10):4417-24. PubMed ID: 15899834
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
[TBL] [Abstract][Full Text] [Related]
15. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
16. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
17. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors.
Yamamoto N; Shimizu T; Yonemori K; Kitano S; Kondo S; Iwasa S; Koyama T; Sudo K; Sato J; Tamura K; Tomomatsu J; Ono M; Fukuda N; Takahashi S
Invest New Drugs; 2021 Aug; 39(4):1036-1046. PubMed ID: 33560503
[TBL] [Abstract][Full Text] [Related]
19. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
20. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]